For: | Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v23/i6/1090.htm |
Number | Citing Articles |
1 |
Osamu Maeda, Yuichi Ando. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World Journal of Gastrointestinal Oncology 2019; 11(7): 518-526 doi: 10.4251/wjgo.v11.i7.518
|
2 |
Hiroyuki Ohnuma, Yasushi Sato, Naoki Onoyama, Kota Hamaguchi, Naotaka Hayasaka, Masanori Sato, Kazuyuki Murase, Kohichi Takada, Koji Miyanishi, Takeshi Murakami, Tatsuya Ito, Takayuki Nobuoka, Ichiro Takemasa, Junji Kato. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. Journal of Cancer Research and Clinical Oncology 2021; 147(8): 2385 doi: 10.1007/s00432-021-03516-7
|
3 |
Jun Kinoshita, Takahisa Yamaguchi, Hideki Moriyama, Sachio Fushida. Current status of conversion surgery for stage IV gastric cancer. Surgery Today 2021; 51(11): 1736 doi: 10.1007/s00595-020-02222-0
|
4 |
Fei Zhang, Xuanzhang Huang, Yongxi Song, Peng Gao, Cen Zhou, Zhexu Guo, Jinxin Shi, Zhonghua Wu, Zhenning Wang. Conversion Surgery for Stage IV Gastric Cancer. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.01158
|
5 |
Nebi Serkan Demirci, Abdulmunir Azizy, Nail Paksoy, İzzet Doğan, Senem Karabulut, Latif Karahan, Didem Tastekin. Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study. Medicine 2024; 103(9): e37259 doi: 10.1097/MD.0000000000037259
|
6 |
Wenjie Zhang, Feng Yu, Yu Wang, Yu Zhang, Lingxin Meng, Yuhua Chi. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway. Oncology Letters 2018; doi: 10.3892/ol.2018.7949
|
7 |
Capecitabine/cisplatin/docetaxel. Reactions Weekly 2017; 1653(1): 92 doi: 10.1007/s40278-017-30520-0
|
8 |
Yao Liang, Osamu Maeda, Kazushi Miyata, Chie Tanaka, Mitsuro Kanda, Dai Shimizu, Masahide Fukaya, Masahiko Koike, Yasuhiro Kodera, Yuichi Ando. A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy. Asia-Pacific Journal of Clinical Oncology 2024; 20(5): 661 doi: 10.1111/ajco.13995
|